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Purpose: The objective of this study was to document the prevalence of high blood pressure (BP) and to
explore its relationship with weight among inpatients with schizophrenia. Additionally, other possible
risk factors impacting BP levels in relation to patients’ demographic characteristics and use of atypical
antipsychotic drugs and medications to reduce blood pressure were analyzed.
Methods: Using medical records, demographic data, and results of physical examination, this cross-
sectional study investigated the prevalence of hypertension and high BP and its association with body
weight among 1,030 inpatients with schizophrenia in a large psychiatric facility in Taiwan.
Results: The prevalence of high BP and hypertension were found to be higher among inpatients with
schizophrenia in Taiwan in comparison with those of the general population in line with the latest
evidence. Hypertensionwas signiﬁcantly associated with body mass index; meanwhile, other risk factors,
including age, gender, length of hospital stay, time since initial schizophrenia diagnosis, medications
used to reduce blood pressure, and atypical antipsychotics, were identiﬁed. However, body mass index
was the most effective predictor of blood pressure in the study.
Conclusion: The ﬁndings of this research shed light on the importance of developing effective weight and
blood pressure monitoring and management programs for inpatients with schizophrenia. There is also
a need for clinical nurses to employ multiple behavioral intervention strategies to minimize risks of high
BP in patients with schizophrenia. We recommend that clinical nurses carefully monitor and control BP
among inpatients with schizophrenia.
Copyright  2012, Korean Society of Nursing Science. Published by Elsevier. All rights reserved.Introduction
Hypertension is a risk factor for many forms of cardiovascular
disease (CVD) and other causes of death related to CVD (Goff et al.,
2005; C.H. Hennekens, A.R. Hennekens, Hollar, & Casey, 2005).
CVD strongly contributes to the excess mortality reported among
schizophrenic patients (Bernardo et al., 2009; von Haussolff-
Juhlin, Bjartveit, Lindström, & Jones, 2009; Räsänen, Hakko,
Viilo, Meyer-Rochow, & Moring, 2003; Sokal, 2004). Hyperten-
sion also is a strong independent risk factor for CVD, and it affects
approximately 15% of the general population in most developed
countries (Hennekens, 1998, 2000), as well as 9e27% of patients
with schizophrenia (Dixon, Postrado, Delahanty, Fischer, &Institute of Bio-Industry
0 Kuo Kuang Rd., Taichung
rean Society of Nursing Science. PLehman, 1999; Goff et al.; Hennekens et al.). Early care interven-
tions offered to patients with mental disorders by nursing
professionals can result in a great improvement in their health
and further encourages a healthy lifestyle (Varcarolis, 2009,
pp. 2e10).
In Taiwan, the lifetime prevalence rate of schizophrenia is
approximately 3 per 1,000 (Tsai & Ku, 2005). Additionally, more than
22% of people with severe mental illness in Taiwan also have
metabolic syndrome (Holt, 2006). Despite the fact that increased
rates of CVD associated with hypertension and metabolic syndrome
are reported among patients with schizophrenia (Saha, Chant, &
McGrath, 2007), few studies have speciﬁcally examined the preva-
lence of elevated blood pressure (BP) and its related risk factors
among such patients in Taiwan. By deﬁnition, the determination of
high BP was madewhen systolic pressure was 130e139 mmHg and/
or diastolic pressure was 85e89 mmHg; hypertension was diag-
nosed when the systolic pressure was greater than 140 mmHg and/
or the diastolic pressure was greater than 90 mmHg (Department of
Health, Taiwan, 2006).ublished by Elsevier. All rights reserved.
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members of the general population, and this condition is partly
exacerbated by marked body weight gain that often accompanies
treatment with some atypical antipsychotics (Allison et al., 1999;
Bridler & Umbricht, 2003). Although there is evidence that obesity
and weight gain resulting from antipsychotic treatment are linked
to metabolic syndrome in patients with schizophrenia (von
Haussolff-Juhlin et al., 2009), far less research has attempted to
clarify the relationship between obesity or weight gain and high BP,
particularly hypertension. Similarly, although the use of antipsy-
chotic agents is common among inpatients with schizophrenia in
Taiwan, there has been little research into this area.
To improve the chances of preventing CVD among patients with
schizophrenia, it is ﬁrst necessary to understand patterns of BP
levels and associated risk factors in this patient group. Even though
hypertension and obesity in schizophrenia are considered largely
treatable and manageable, they have not attracted the attention
they deserve. Ironically, the cost of hypertension-related treatment
is among the highest on the list of national health insurance costs in
Taiwan (Li, Yeh, & Huang, 2006). If earlier attention were paid to
these problems, patients’ well-being and quality of life would be
greatly improved (McDevitt, 2004) and national healthcare costs
would be reduced as well (Lissovoy, Pan, Siak, Hutchins, & Luce,
2009).
Despite an increasing trend to treat schizophrenic patients on an
outpatient basis, a safe and structured environment must be
provided for peoplewhomay place themselves or others at risk due
to their mental disorders (Varcarolis, 2009). Frauenfelder, Müller-
Staub, Needham, and Achterberg (2011) also pointed out the
substantial need to address nursing and self-care problems faced by
adult psychiatric inpatients, to develop and improve practical
guidelines for effective nursing treatment. This need is particularly
acute in Taiwan, where many family caregivers need to be educated
on and to learn the skills for taking care of patients with mental
illness (Wei, Cooke, Moyle, & Creedy, 2010). Therefore, patients
with schizophrenia in Taiwan are comparatively in better care
when institutionalized for the present. To the best of our team’s
knowledge, there is no well-established community-based care
system yet available for patients diagnosed with schizophrenia
throughout Taiwan, and most are institutionalized in psychiatric
facilities. This highlights the importance of caregiving or inter-
vention services provided to schizophrenic inpatients by clinical
nurses in Taiwan.
This study was designed to document the prevalence of high BP
and hypertension among inpatients with schizophrenia in one of
the largest psychiatric hospitals in Taiwan. Furthermore, we
investigated the relationship between patients’ BP levels and body
weight, as identiﬁed by prior relevant research based on body mass
index (BMI) by Coodin (2001), Meyer (2002), and Vieweg et al.
(2004). In addition, several possible risk factors concerning use of
atypical antipsychotics (Katzung & Trevor, 2002; Meyer & Quenzer,
2005) and antihypertensive medications were also examined.
Although patients’ demographic characteristics, such as age,
gender, education level, time since initial schizophrenia diagnosis,
and length of hospital stay and so forth have yet to be conﬁrmed
with regard to their consistent effects on BP levels among inpa-
tients with schizophrenia, they were included for analysis in the
present study as an exploratory research attempt.
To explore the hypothesis that schizophrenic patients are
inclined to develop hypertension, the study ﬁrst attempted to
investigate the phenomenon of high BP among inpatients with
schizophrenia in Taiwan. Furthermore, implications for nursing
care tailor-made for these inpatients were discussed. The results
could also have important implications for improved mental
health care.Methods
Participants
Participants in this study included 1,030 inpatients with
schizophrenia in a psychiatric hospital with one of the largest
populations of schizophrenic patients in Taiwan. For inclusion in
the study, patients met the following criteria; (a) having a diagnosis
of schizophrenia according to Diagnostic and Statistical Manual of
Mental Disorders IV (DSM-IV) criteria, and (b) being hospitalized
longer than 6 months. Patients diagnosed with dementia, or those
who were seriously ill, or who were unable to communicate were
excluded from the study.
The number of patients who met the study criteria was 1,061
(638 males and 423 females); data were collected from 1,030
patients (614 males and 416 females) who agreed to participate in
this study. The research ethics committee of this psychiatric facility
approved the study protocols; permission from the ward managers
was sought prior to interviewing any nurses and inpatients. After
analyzing medical records, and measuring height, weight, and BP,
the valid sample consisted of 1,030 schizophrenia inpatients. In
addition, there were no statistically signiﬁcant differences between
the participants and the nonparticipants in terms of the informa-
tion gathered for this investigation based on analyses of chi-square
and coefﬁcient of variation (p> .05).
Measurements and study variables
Data were collected over a 5-month period. In this cross-
sectional study, we recorded and analyzed the participants’
medical records, BP levels, height, and weight. Demographic char-
acteristics included age, gender, education level, length of hospital
stay, and time since the initial schizophrenia diagnosis. Medication
protocols were also studied, including use of atypical antipsychotic
agents and antihypertensive medications. Overweight was deﬁned
as a bodymass index (BMI, kg/m2) between 24 kg/m2 and 27 kg/m2
for both males and females. Obesity was deﬁned as a BMI  27 kg/
m2 (Department of Health, Taiwan, 2006). A diagnosis of high BP
was made when systolic pressure was 130e139 mmHg and/or
diastolic pressure was 85e89 mmHg, and hypertension was diag-
nosed when the systolic pressure 140 mmHg and/or the diastolic
pressure was  90 mmHg (Department of Health, Taiwan).
Procedures
The study was approved by the research ethics committee of the
hospital, and a total of 1,030 participants gave written informed
consent to join in the study after being briefed on the research
purpose and procedure. The data for this study were collected
under the supervision of the designated physician and executive
managers of the hospital by reviewing medical records in both
digital and hard copy form. Registered nurses measured the
patients’ BP, height and weight. BP was measured with a mercury
sphygmomanometer after the patient had rested for at least 5
minutes. BP was remeasured with the patient seated, with the
sphygmomanometer and the arm at the same height as the heart.
The average value was calculated from two contiguous measure-
ments. In addition, BP was measured on the 5th and 20th days of
each month; thus, eight BP measurements for each patient were
collected during the study period. For systolic BP (SBP) and diastolic
BP (DBP), the mean of each patient’s eight BP measurements was
calculated accordingly for analysis. Height and weight were
measured with calibrated and qualiﬁed scales. BMI, calculated from
the measured height and weight, was used as the criterion for
obesity.
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The datawere analyzed with SPSS version 15 (SPSS Inc., Chicago,
IL, USA). A descriptive analysis was done ﬁrst to understand the
distribution of all the patients’ data, such as demographic variables,
disease history, and medication history. The prevalence of high BP,
hypertension, overweight, and obesity was analyzed and stratiﬁed
by age and gender. Multiple regressions were used to determine
whether or not the demographic characteristics, use of atypical
antipsychotics, and antihypertensive medication, and BMI could
be used to predict BP and to establish the predictive power of BMI
for BP.
Results
The average age of participants was 48 years. In the study
sample, 59.6% were males and 40.4% were females; 29.8% had
completed junior high school and 28.3% had completed senior high
school. The average length of hospital stay was 9 years, and the
average period of time since initial schizophrenia diagnosis was 20
years. Of the total number of participants, only 10.1% (n¼ 104) used
medicine to reduce BP, and 41.6% (n ¼ 428) used medicine of
atypical antipsychotics. Descriptive data concerning participants’
baseline characteristics can be found in Table 1.
Prevalence of high BP among inpatients with schizophrenia
A total of 192 subjects had high BP. The mean prevalence rate of
high BP was 16% (males, 21.4%; females, 10.6%). The prevalence rateTable 1 Baseline Characteristics of Participants
Variables n (%) M (SD)
Age (yr) 1,030 (100.0) 48 (12.2)
21e40 303 (29.4)
41e60 602 (58.5)




Education level 1,023 (100.0)
Dyslexia 69 (6.7)
Elementary school 237 (23.2)
Junior high school 305 (29.8)
Senior high school 290 (28.3)
College 113 (11.0)
Graduate school 9 (0.9)
Length of hospital stay (yr) 1,030 (100.0) 9 (6.8)




> 20 89 (8.6)
Period of time since initial
schizophrenia diagnosis
1,028 (100.0) 20 (10.7)





> 50 3 (0.3)
Medicine to reduce BP 1,030 (100.0)
Yes 104 (10.1)
No 926 (89.9)
Medicine of atypical antipsychotics 1,030 (100.0)
Yes 428 (41.6)
No 602 (58.4)
Note. BP¼ blood pressure.of high BP was greater for males than for females at each age
interval. After the age of 30 years, the prevalence rate of high BP for
both males and females increased gradually, but decreased during
the 50e59-year age interval for males and 60e69-year interval for
females. The prevalence rate for BP then rose in males after the age
of 70. The number of those who had hypertension, including those
whowere diagnosed with hypertension before this study and those
who took medication to reduce BP, was 168. The mean prevalence
rate of hypertension was 15.9% (males, 18.1% and females, 13.7%).
Before the age of 50, the prevalence rate of hypertension for men
was higher than for women. The prevalence rate of hypertension
for both males and females increased gradually along with an
increase of age before 50 years old. Information about elevated BP
by age and gender is detailed in Table 2.
Prevalence of overweight and obesity among inpatients with
schizophrenia
In the current study, 270 patients were found to be overweight,
which contributed to the ﬁnding that 26.1% of the subjects were
overweight (males, 27.6%; females, 24.6%). Also, 372 patients were
found to be obese; the mean prevalence rate of obesity was 36.3%
(males, 36.5%; females, 36.1%). Between the ages of 30 and 49 years,
and over 70 years, the prevalence rate of being overweight and
obesity among males was higher than that of females at each age
interval. The average BMI in this study samplewas 25.2 kg/m2 (25.0
in males and 25.3 in females). As a result, normal healthy weight
was uncommon among our study population. More than 50% of the
males and females in all age groups had a BMI > 24.0 kg/m2. The
BMI, overweight, and obesity information of these subjects by age
and gender are presented in Table 3.
Effects of body weight as a predictive risk factor
The predictive power for BP based on BMI, demographic char-
acteristics, and use of atypical antipsychotics and antihypertensive
medications were analyzed using multiple linear regressions. The
following independent variables, gender and medication protocols,
were transformed into dummy variables for multiple linear
regressions.
Model 1 (Table 4) used a full attributes set to predict both
systolic and diastolic blood pressure. The result showed that age,
gender, length of hospital stay, period of time since initial schizo-
phrenia diagnosis, use of medication to reduce BP, and BMI had
signiﬁcant predictive power for systolic blood pressure (F¼ 27.28,
p< .001, R2¼ .19), explaining 19% of variance in predicting systolic
pressure. As for diastolic pressure, age, gender, BMI, length of
hospital stay, time since initial schizophrenia diagnosis, and use of
atypical antipsychotics and medications to reduce BP had signiﬁ-
cant predictive power (F¼ 18.27, p< .001, R2¼ .13); explaining 13%
of variance in predicting DBP.
Model 2 (Table 5) analyzed whether BMI predicted for BP levels
after controlling for the patients’ use of medications. For both SBP
and DBP, patients’ medication protocols and BMI had signiﬁcant
predictive power (F¼ 25.59, p< .001, R2¼ .09, and F¼ 21.38,
p< .001, R2¼ .07, respectively), accounting for 9% and 7% of the total
variance in SBP and DBP respectively. Among these contributing
factors based on regression model 1 and 2, BMI was evidenced as
amoreeffectivepredictorof BP in the study (Model 1:b¼ .23 for SBP,
and b¼ .24 for DBP; Model 2: b¼ .21 for SBP, and b¼ .23 for DBP).
Discussion
The mean prevalence rate of hypertension and high BP for study
participants was 15.9% (18.1% in males and 13.7% in females) and
Table 2 Prevalence of High Blood Pressure (HBP) and Hypertension Stratiﬁed by Age and Gendera
Age (yr) Males Females
SBP (M SD) DBP (M SD) HBP n (%) Hypertension n (%) SBP (M SD) DBP (M SD) HBP n (%) Hypertension n (%)
<30 121.2 13.2 74.1 7.5 7 (22.6) 2 (6.5) 111.4 6.4 69.8 5.2 0 0
30e39 122.5 10.5 76.9 7.4 33 (21.6) 16 (10.5) 113.3 9.7 72.5 7.2 5 (6.6) 3 (3.9)
40e49 122.6 11.9 77.5 7.9 46 (21.5) 36 (16.8) 116.4 9.4 74.4 7.5 9 (7.3) 14 (11.3)
50e59 122.3 13.3 77.6 8.5 30 (22.6) 23 (17.3) 118.9 11.2 74.8 7.0 25 (16.2) 28 (18.2)
60e69 120.4 14.1 72.6 10.7 6 (28.6) 4 (1.9) 119.7 10.1 73.5 6.3 4 (8.9) 9 (20.0)
70 132.0 11.2 80.6 8.6 26 (41.9) 30 (48.4) 129.5 20.4 71.5 9.1 1 (2.5) 3 (7.5)
Total 123.3 12.3 77.3 8.2 148 (21.4) 111 (18.1) 117.1 10.6 73.9 7.1 44 (10.6) 57 (13.7)
Notes. SBP¼ systolic blood pressure; DBP¼ diastolic blood pressure.
a HBP refers to BP at 130e139 mmHg/85e89 mmHg, and hypertension refers to blood pressure higher than 140 mmHg/90 mmHg.
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alence of hypertension and high BP was higher in our participants
than in the general population in Taiwan (hypertension: 11.3% in
males and 11.2% in females; Department of Health, Taiwan, 2002;
Pan, 1991). As a result, the prevalence of hypertension was more
common among inpatients with schizophrenia compared with the
general population, echoing the results in the literature. This
ﬁnding also corroborates research results of Bernardo et al.
(2009), Bresee, Majumdar, Patten, and Johnson (2010), and Liao
et al. (2011) that patients with schizophrenia are more likely to
develop hypertensive disorders than are members of the general
population.
Results from this study further indicated a signiﬁcant difference
in the overall prevalence of obesity and overweight in inpatients
with schizophrenia compared to the general population. The
overall prevalence of obesity in this study was 36.3% (36.5% in
males and 36.1% in females); the prevalence of overweight was
26.1% (27.6% in males and 24.6% in females). This is higher than the
overall prevalence of obesity (14.6% in males and 15.8% in females)
and being overweight (17.5% in males and 15.9% in females) in the
general Taiwanese population reported in the most recent National
Nutrition Survey (Department of Health, Taiwan, 2006). The study
data indicated that inpatients with schizophrenia are actually
heavier than the general public.
According to Allison et al. (1999), Bridler and Umbricht (2003),
and Wetterling (2001), the use of atypical antipsychotics particu-
larly leads to substantial weight gain. The antagonism of central 5-
HT2 receptors seems to play an important role. It is believed that
this blockade results in increased appetite and excessive food
intake. Weight gain occurs over the whole dosage range, consistent
with the observation that even small doses of these medications
result in an almost total blockade of serotonergic receptors (Gefvert
et al., 1998; Kapur, 1998; Kapur et al., 1998). So, results of the
present study showed that patients taking atypical antipsychotics
may be at risk for obesity and elevated BP. This ﬁnding is consistent
with the research of Henderson et al. (2004). Obesity is a serious
medical condition and has serious psychosocial consequences.Table 3 Prevalence of Obesity and Overweight Stratiﬁed by Age and Gendera
Age (yr) Males
BMI (M SD) Overweight n (%) Obesity n (%) R Ov/o
< 30 25.0 5.2 5 (16.1) 11 (35.5) 0.45
30e39 25.9 4.8 44 (29.1) 59 (39.1) 0.74
40e49 25.6 4.5 58 (27.4) 81 (38.2) 0.72
50e59 25.2 4.2 36 (27.3) 49 (37.1) 0.74
60e69 25.3 4.2 9 (42.9) 6 (28.6) 1.5
 70 23.9 3.9 16 (25.8) 16 (25.8) 1.0
Total 25.0 4.5 168 (27.6) 222 (36.5) 0.76
Note. BMI¼ body mass index; R Ov/ob¼ ratio of overweight/obesity.
a Obesity refers to BMI  27 kg/m2 and overweight refers to BMI of 24e26.9 kg/m2.Being overweight or obese is a threat to one’s health and longevity
and is associated with an increased risk of several medical condi-
tions, all of which may signiﬁcantly affect a psychotic patient’s
sense of well-being and self-esteem.
Additionally, the research ﬁndings on BMI appear to be consis-
tent with research results in other countries, such as in Canada
(Coodin, 2001) and in the United States (Meyer, 2002; Vieweg et al.,
2004). There are many health risks associated with obesity, such as
hypertension, coronary artery disease, CVD, and type 2 diabetes
mellitus (National Heart, Lung, and Blood Institute, 2001). In the
current study, BMI was independently associated with the risk of
hypertension. After controlling for patients’ medication protocols,
the analysis showed a 0.21 mmHg increase in SBP and a 0.23 mmHg
increase in diastolic pressure for every 1 kg/m2 increase in BMI. Our
result is similar to research ﬁndings of Meyer and Quenzer (2005)
and Katzung and Trevor (2002) which showed that BMI has crit-
ical effects on high BP. Thus, controlling body weight is an impor-
tant way to help prevent hypertension or high BP. To be effective,
a coordinated approach is needed. Inpatients should be encouraged
to get involved and to collaborate with nurses to develop and
implement their own care plan, including both weight manage-
ment and BP surveillance.
The results of this study conﬁrmed independent positive rela-
tions between the BMI and BP levels among inpatients with
schizophrenia. BP levels and the incidence of hypertension were
higher among the patients with schizophrenia than among the
general population in Taiwan. Patients with schizophrenia have an
increased risk of dying from CVD, and some researchers have
reported that the risk of death from this causewas nearly twice that
of other patient populations (Bernardo et al., 2009; Curkendall, Mo,
Glasser, Rose, & Jones, 2004; Ösby, Correia, Brandt, Ekbom, &
Sparén, 2000). Since high BP is an important indicator of CVD, it
should be identiﬁed and prevented as early as possible in patients
with schizophrenia. It also reﬂects both the quality of psychiatric
and medical care and the effectiveness of preventive programs. We
recommend that clinical nurses carefully monitor and control BP
among inpatients with schizophrenia. Consequently, continualFemales
b BMI (M SD) Overweight n (%) Obesity n (%) R Ov/ob
27.5 5.4 3 (23.1) 7 (53.8) 0.43
26.3 5.4 19 (25.3) 30 (40.0) 0.63
25.7 4.5 34 (27.4) 46 (37.1) 0.74
24.7 4.2 36 (23.4) 51 (33.1) 0.71
24.7 4.2 10 (22.2) 15 (33.3) 0.67
21.8 4.6 0 1 (25.0) 0.00
25.3 4.6 102 (24.6) 150 (36.1) 0.68




Systolic blood pressurea Diastolic blood pressureb
b t p b t pc
Age .176 5.13*** < .001 .124 3.51*** < .001
Gender .267 9.01*** < .001 .204 6.66*** < .001
Education level .004 0.13 .900 .035 1.17 .243
LOHS .114 3.55*** < .001 .107 3.22** .001
POTSISD .075 2.29* .022 .099 2.90** .004
MTRBP .015 4.90*** < .001 .087 2.81** .005
MOAA .042 1.423 .155 .077 2.51* .012
BMI .230 7.95*** < .001 .238 7.95*** < .001
Notes. LOHS¼ length of hospital stay; POTSISD¼ period of time since initial
schizophrenia diagnosis; MTRBP¼medicine to reduce blood pressure;
MOAA¼medicine of atypical antipsychotics; BMI¼ body mass index.
a F¼ 27.28; df¼ 1,016; p<.001; adjusted R2¼ .19; b F¼ 18.27; df¼ 1,016; p<.001;
adjusted R2¼ .13; c p obtained by correlation between blood pressure and age,
gender, education level, LOHS, POTSISD, MTRBP, MOAA, and BMI.
*p< .05. **p< .01. ***p< .001.
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tients with schizophrenia.
Limitations
The study ﬁndings provide evidence on prevalence of high BP
and point to its association with bodyweight factors among inpa-
tients with schizophrenia. It is apparent that a range of risk factors
for higher BP, including age, gender, length of hospital stay, period
of time since initial schizophrenia diagnosis and medicine to
reduce BP is also present in this patient population. Nevertheless,
a limitation of the present research is the lack of information
related to assessment of their lifestyle, such as diet, smoking, and
exercise behaviors which may also affect the high blood pressure of
patients with schizophrenia (von Haussolff-Juhlin et al., 2009;
Kurzhaler & Fleischhacker, 2001; Ogawa, Miyamoto, & Kawakami,
2011; Robin, 2003). As such, we are unable to correlate their life-
style variables to different levels of high blood pressure. This also
points out what we can continue to explore in future research.
Moreover, the recruitment of participants in this study solely
from one psychiatric facility may have biased the results such that it
may not be representative of the general population of patients
with schizophrenia. Finally, the data were collected by measuring
BP eight times and corrected to make comparisons with those of
the general population in Taiwan, as revealed in the prior studies.
Thus, there is the possibility of a comparison error. Despite the
strong relationships between BMI and high BP found in inpatients
with schizophrenia, the current cross-sectional design restricts
conclusions regarding the causality of these associations. Prospec-
tive longitudinal studies on both inpatients and outpatients with
schizophrenia are required to evaluate how BMI and BP change
over time or if their interactions strengthen.Table 5 Prediction for Medication Protocols and BMI in Multiple Regression
Variables
(model 2)
Systolic blood pressurea Diastolic blood pressureb
b t p b t p
MTRBP .188 6.16*** < .001 .112 3.65*** < .001
MOAA .082 2.66** .008 .105 3.37** .001
BMI .207 6.869*** < .001 .225 7.41*** < .001
Note. MTRBP¼medicine to reduce blood pressure; MOAA¼medicine of atypical
antipsychotics; BMI¼ body mass index.
p-value obtained by correlation between blood pressure and MTRBP, MOAA, and
BMI.
a F¼ 25.59;df¼ 1,025;p¼ .000; adjustedR2¼ .09; b F¼ 21.38;df¼ 1,025;p¼ .000;
adjusted R2¼ .07.
*p< .05. **p< .01. ***p< .001.Conclusion
The current study promotes better understanding of the prev-
alence of high BP by exploring its possible risk factors concerning
patients’ demographic characteristics and medication protocols, in
addition to clarifying its relationship to weight gain among inpa-
tients with schizophrenia. High BP problems are more common
among inpatients with schizophrenia, mainly due to weight gain or
obesity. Such problems warrant more attention because of their
direct impact on mortality rates from CVD and possibly indirect
effects on quality of life as well as healthcare costs.
Equipping nurses with sufﬁcient knowledge of these risk factors
related to body weight is vital, for they may be able to “spot”
potential high BP or hypertension in advance by adequate screening
practices, and thus be able to alert the wider multidisciplinary
team. Clinical nurses also play a key coordinating role in this
regard; their input may help this inpatient group minimize risks of
hypertension and subsequent CVD. Consequently, our ﬁndings
illuminate the importance of developing effective weight and BP
monitoring and management programs speciﬁcally taking into
consideration of patients’ age, gender, and length of initial schizo-
phrenia diagnosis and hospital stay, which are also found to be
related to high BP in the present study.
Given the high prevalence of obesity and its signiﬁcant impacts
on high BP, further research is particularly necessary to examine
weight gain mechanisms and psychosocial mediators that facilitate
adjustment of obesity in schizophrenia.Conﬂict of interest
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